Alumis

Alumis

Yahoo Finance • 2 days ago

Merck (MRK) Withdrew a Cancer Filing. Is the Drug’s Promise Still Intact?

Merck & Co., Inc. (NYSE:MRK) and Daiichi Sankyo announced on September 25 that they voluntarily withdrew the U.S. application for ifinatamab deruxtecan in adults whose extensive-stage small-cell lung cancer progressed during or after plati... Full story

Yahoo Finance • 28 days ago

Sector Update: Healthcare Stocks Advance Late Afternoon

Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index and the State PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 28 days ago

Sector Update: Healthcare Stocks Advance Wednesday Afternoon

Healthcare stocks were higher Wednesday afternoon, with the NYSE Healthcare Index adding 0.7% and th PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 months ago

High-flyer healthcare stocks: Ten names with strong momentum, weak valuations

[Heart Health Concept] Eoneren/E+ via Getty Images Wall Street investors are increasingly seeking refuge in high-performing equity plays as volatile healthcare markets continue to shift, forcing a critical evaluation of stock price veloci... Full story

Yahoo Finance • 4 months ago

What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors

Key Points Saturn V sold 1,504,880 shares of Ocular Therapeutix in the first quarter; the estimated transaction value was $14.34 million. Meanwhile, the quarter-end position value declined by $18.27 million, reflecting both share sales an... Full story

Yahoo Finance • 4 months ago

Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish

Octagon Capital Advisors cut its stake in Dianthus Therapeutics(NASDAQ:DNTH) by 470,000 shares, an estimated $27.22 million trade based on quarterly average pricing, according to a May 15, 2026 SEC filing. What happened According to a SE... Full story

Yahoo Finance • 6 months ago

Commit To Buy Alumis At $15, Earn 34.6% Annualized Using Options

Investors considering a purchase of Alumis Inc (Symbol: ALMS) stock, but cautious about paying the going market price of $23.76/share, might benefit from considering selling puts among the alternative strategies at their disposal. One int... Full story

Yahoo Finance • 6 months ago

Alumis' Drug 'Very Positive' for Treatment of Psoriasis, Systemic Lupus Erythematosus, Oppenheimer Says

Alumis' (ALMS) recent phase 3 results for its psoriasis treatment envudeucitinib is "very positive" PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 6 months ago

Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis

Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%) Quality‑of‑life improvements and itch relief emerged ahead of PASI 90 skin c... Full story

Yahoo Finance • 7 months ago

Alumis to Present at the Leerink Partners Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that Mar... Full story

Yahoo Finance • 10 months ago

Stocks Pressured by Higher Bond Yields

The S&P 500 Index ($SPX) (SPY) today is down -0.15%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -0.10%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.20%.  March E-mini S&P futures (ESH25) are down -0.16%, and March E-mini N... Full story

Yahoo Finance • 11 months ago

Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today reporte... Full story

Yahoo Finance • last year

Alumis to Participate in Upcoming September Investor Conferences

SOUTH SAN FRANCISCO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the... Full story

Yahoo Finance • last year

TYK2 Inhibitors Market to Drive Enormous Growth by 2034 Due to Strong Pipeline and Expanding Indications | DelveInsight

The TYK2 inhibitor market is expected to witness substantial growth in the coming years, driven by the increasing prevalence of autoimmune diseases, robust clinical pipeline activity, and expanding regulatory approvals. Several key players... Full story

Yahoo Finance • last year

Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus

-Topline Readout Expected in Q3 2026- SOUTH SAN FRANCISCO, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-media... Full story

Yahoo Finance • last year

Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary

SOUTH SAN FRANCISCO, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the promo... Full story

Yahoo Finance • last year

Alumis to Present at the Jefferies Global Healthcare Investor Conference

SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that Marti... Full story

Yahoo Finance • last year

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the comple... Full story

Yahoo Finance • last year

Alumis Completes Merger with ACELYRIN

SOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that it ha... Full story

Yahoo Finance • last year

Alumis Stockholders Approve Merger with ACELYRIN

SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve... Full story